Pleiotropic signaling evoked by tumor necrosis factor in podocytes

American Journal of Physiology - Renal Physiology

Volumn 309, Issue 2, 2015, Pages F98-F108

  Abkhezr, Mousa ^a   Kim, Eun Young ^a   Roshanravan, Hila ^a   Nikolos, Fotis ^a   Thomas, Christoforos ^a   Hagmann, Henning ^b   Benzing, Thomas ^b   Dryer, Stuart E ^a,c  

^a University of Houston   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Glomerulosclerosis; Inflammation; Member 6; Podocyte; Subfamily C; Transient receptor potential cation channel; Tumor necrosis factor

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DIACYLGLYCEROL; PODOCIN; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; TRANSCRIPTION FACTOR RELA; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; NFATC1 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRPC6 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CATION TRANSPORT; CELL NUCLEUS; CELL SURFACE; CONTROLLED STUDY; ELECTRIC CURRENT; MOUSE; NONHUMAN; PLEIOTROPY; PODOCYTE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; STEADY STATE; ADULT; ANIMAL; CELL LINE; FOCAL GLOMERULOSCLEROSIS; HUMAN; MALE; METABOLISM;

ADULT; ANIMALS; CELL LINE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; MALE; MICE; NFATC TRANSCRIPTION FACTORS; PODOCYTES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRPC CATION CHANNELS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84937856039     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00146.2015     Document Type: Article

References (76)

1. Abkhezr M, Dryer SE. Angiotensin II and canonical transient receptor potential-6 activation stimulate release of a signal transducer and activator of transcription 3-activating factor from mouse podocytes. Mol Pharmacol 86: 150–158, 2014.
2. Abkhezr M, Dryer SE. STAT3 regulates steady-state expression of synaptopodin in cultured mouse podocytes. Mol Pharmacol 87: 231–239, 2015.
3. Aliprantis AO, Glimcher LH. NFATc1 in inflammatory and musculoskeletal conditions. Adv Exp Med Biol 658: 69–75, 2010.
4. Al-Lamki RS, Mayadas TN. TNF receptors: signaling pathways and contribution to renal dysfunction. Kidney Int 87: 281–296, 2015.
5. Anderson M, Kim EY, Hagmann H, Benzing T, Dryer SE. Opposing effects of podocin on the gating of podocyte TRPC6 channels evoked by membrane stretch or diacylglycerol. Am J Physiol Cell Physiol 305: C276–C289, 2013.
6. Anderson M, Roshanravan H, Khine J, Dryer SE. Angiotensin II activation of TRPC6 channels in rat podocytes requires generation of reactive oxygen species. J Cell Physiol 229: 434–442, 2014.
7. Aringer M, Smolen JS. Cytokine expression in lupus kidneys. Lupus 14: 13–18, 2005.
8. Ashizawa M, Miyazaki M, Abe K, Furusu A, Isomoto H, Harada T, Ozono Y, Sakai H, Koji T, Kohno S. Detection of nuclear factor-κB in IgA nephropathy using Southwestern histochemistry. Am J Kidney Dis 42: 76–86, 2003.
9. Assadi F. Neonatal nephrotic syndrome associated with placental transmission of proinflammatory cytokines. Pediatr Nephrol 26: 1–3, 2010.
10. Bakr A, Shokeir M, El-Chenawi F, El-Husseni F, Abdel-Rahman A, El-Ashry R. Tumor necrosis factor-α production from mononuclear cells in nephrotic syndrome. Pediatr Nephrol 18: 516–520, 2003.
11. Barisoni L, Schnaper HW, Kopp JB. A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2: 529–542, 2007.
12. Baud L, Fouqueray B, Philippe C, Amrani A. Tumor necrosis factor alpha and mesangial cells. Kidney Int 41: 600–603, 1992.
13. Bertani T, Abbate M, Zoja C, Corna D, Perico N, Ghezzi P, Remuzzi G. Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol 134: 419–430, 1989.
14. Bitzan M, Babayeva S, Vasudevan A, Goodyer P, Torban E. TNF pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation. Pediatr Nephrol 27: 2217–2226, 2012.
15. Bustos C, González E, Ross M, Alonso JL, Egido J. Increased TNFα synthesis in peripheral blood mononuclear cells of children with idiopathic nephrotic syndrome. Eur J Clin Invest 24: 799–805, 1994.
16. Chana RS, Martin J, Rahman EU, Wheeler DC. Monocyte adhesion to mesangial matrix modulates cytokine and metalloproteinase production. Kidney Int 63: 889–898, 2003.
17. Chugh SS, Clement LC, Macé C. New insights into human minimal change disease: lessons from animal models. Am J Kidney Dis 59: 284–292, 2012.
18. D’Agati VD. Pathobiology of focal segmental glomerulosclerosis: new developments. Curr Opin Nephrol Hypertens 21: 243–250, 2012.
19. Dai Y, Gu L, Yuan W, Yu Q, Ni Z, Ross MJ, Kaufman L, Xiong H, Salant DJ, He JC, Chuang PY. Podocyte-specific deletion of signal transducer and activator of transcription 3 attenuates nephrotoxic seruminduced glomerulonephritis. Kidney Int 84: 950–961, 2013.
20. Drewe E, McDermott EM, Powell RJ. Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med 343: 1044–1045, 2000.
21. Dryer SE, Reiser J. TRPC6 channels and their binding partners in podocytes: role in glomerular filtration and pathophysiology. Am J Physiol Renal Physiol 299: F689–F701, 2010.
22. Feng X, Lu TC, Chuang PY, Fang W, Ratnam K, Xiong H, Ouyang X, Shen Y, Levy DE, Hyink D, Klotman M, D’Agati V, Iyengar R, Klotman PE, He JC. Reduction of Stat3 activity attenuates HIV-induced kidney injury. J Am Soc Nephrol 20: 2138–2146, 2009.
23. Gu L, Dai Y, Xu J, Mallipattu S, Kaufman L, Klotman PE, He JC, Chuang PY. Deletion of podocyte STAT3 mitigates the entire spectrum of HIV-1-associated nephropathy. AIDS 27: 1091–1098, 2013.
24. Heeringa SF, Möller CC, Du J, Yue L, Hinkes B, Chernin G, Vlangos CN, Hoyer PF, Reiser J, Hildebrandt F. A novel TRPC6 mutation that causes childhood FSGS. PLos One 4: e7771, 2009.
25. Hofstra JM, Lainez S, van Kuijk WH, Schoots J, Baltissen MP, Hoefsloot LH, Knoers NV, Berden JH, Bindels RJ, van der Vlag J, Hoenderop JG, Wetzels JF, Nijenhuis T. New TRPC6 gain-of-function mutation in a nonconsanguineous Dutch family with late-onset focal segmental glomerulosclerosis. Nephrol Dial Transplant 28: 1830–1838, 2003.
26. 2+ mobilization after TNF or fat exposure. PLos One 9: e87068, 2014.
27. Ilatovskaya DV, Palygin O, Chubinskiy-Nadezhdin V, Negulyaev YA, Ma R, Birnbaumer L, Staruschenko A. Angiotensin II has acute effects on TRPC6 channels in podocytes of freshly isolated glomeruli. Kidney Int 86: 506–514, 2014.
28. Jung S, Mühle A, Schaefer M, Strotmann R, Strotmann R, Schultz G, Plant TD. Lanthanides potentiate TRPC5 currents by an action at extracellular sites close to the pore mouth. J Biol Chem 278: 3562–3571, 2003.
29. 2+-ATPase expressions via the promoter methylation in cardiomyocytes. Crit Care Med 38: 217–222, 2010.
30. Kastl L, Sauer SW, Ruppert T, Beissbarth T, Becker MS, Süss D, Krammer PH, Gülow K. TNF-α mediates mitochondrial uncoupling and enhances ROS-dependent cell migration via NF-κB activation in liver cells. FEBS Lett 588: 175–183, 2014.
31. Kim EY, Anderson M, Dryer SE. Insulin increases surface expression of TRPC6 channels in podocytes: role of NADPH oxidases and reactive oxygen species. Am J Physiol Renal Physiol 302: F298–F307, 2012.
32. Kim EY, Anderson M, Wilson C, Dryer SE. NOX2 interacts with podocyte TRPC6 channels and contributes to their activation by diacylglycerol: essential role of podocin in formation of this complex. Am J Physiol Cell Physiol 305: C960–C971, 2013.
33. Kim YH, Goyal M, Kurnit D, Wharram B, Wiggins J, Holzman L, Kershaw D, Wiggins R. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 60: 957–968, 2001.
34. King CC, Sastri M, Chang P, Pennypacker J, Taylor SS. The rate of NF-κB nuclear translocation is regulated by PKA and A kinase interacting protein 1. PLos One 6: e18713, 2011.
35. Kistler AD, Singh G, Altintas MM, Yu H, Fernandez IC, Gu C, Wilson C, Srivastava SK, Dietrich A, Walz K, Kerjaschki D, Ruiz P, Dryer S, Sever S, Dinda AK, Faul C, Reiser J. Transient receptor potential channel 6 (TRPC6) protects podocytes during complementmediated glomerular disease. J Biol Chem 288: 36598–36609, 2013.
36. Kong SK, Fung KP, Choy YM, Lee CY. Slow increase in intranuclear and cytosolic free calcium concentrations in L929 cells is important in tumour necrosis factor-α-mediated cell death. Oncology 54: 55–62, 1997.
37. Krall P, Canales CP, Kairath P, Carmona-Mora P, Molina J, Carpio JD, Ruiz P, Mezzano SA, Li J, Wei C, Reiser J, Young JI, Walz K. Podocyte-specific overexpression of wild type or mutant trpc6 in mice is sufficient to cause glomerular disease. PLos One 5: e12859, 2010.
38. Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int 67: 404–419, 2005.
39. Kuwahara K, Wang Y, McAnally J, Richardson JA, Bassel-Duby R, Hill JA, Olson EN. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J Clin Invest 116: 3114–3126, 2006.
40. Lama G, Luongo I, Tirino G, Borriello A, Carangio C, Salsano ME. T-lymphocyte populations and cytokines in childhood nephrotic syndrome. Am J Kidney Dis 39: 958–965, 2002.
41. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H. Persistently activated Stat3 maintains constitutive NF-κB activity in tumors. Cancer Cell 15: 283–293, 2009.
42. Leroy S, Guigonis V, Bruckner D, Emal-Aglae V, Deschênes G, Bensman A, Ulinski T. Successful anti-TNFα treatment in a child with posttransplant recurrent focal segmental glomerulosclerosis. Am J Transplant 9: 858–861, 2009.
43. Li Z, Wang C, Prendergast GC, Pestell RG. Cyclin D1 functions in cell migration. Cell Cycle 5: 2440–2442, 2006.
44. Mantovani A. Molecular pathways linking inflammation and cancer. Curr Mol Med 10: 369–373, 2010.
45. McCarthy ET, Sharma R, Sharma M, Li JZ, Ge XL, Dileepan KN, Savin VJ. TNFα increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 9: 433–438, 1998.
46. Möller CC, Wei C, Altintas MM, Li J, Greka A, Ohse T, Pippin JW, Rastaldi MP, Wawersik S, Schiavi S, Henger A, Kretzler M, Shankland SJ, Reiser J. Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol 18: 29–36, 2007.
47. Mori K, Yoshida K, Komatsu A, Tani J, Nakagawa Y, Hoshikawa S, Ito S. Autoinduction of tumor necrosis factor-α in FRTL-5 rat thyroid cells. J Endocrinol 187: 17–24, 2005.
48. Murphy HS, Shayman JA, Till GO, Mahrougui M, Owens CB, Ryan US, Ward PA. Superoxide responses of endothelial cells to C5a and TNF-α: divergent signal transduction pathways. Am J Physiol Lung Cell Mol Physiol 263: L51–L59, 1992.
49. Nakamura T, Ebihara I, Fukui M, Takahashi T, Tomino Y, Koide H. Altered glomerular steady-state levels of tumour necrosis factor-α mRNA during nephrotic and sclerotic phases of puromycin aminonucleoside nephrosis in rats. Clin Sci 84: 349–356, 1993.
50. Nakayama S, Yokote T, Kobayashi K, Hirata Y, Akioka T, Hiraoka N, Oka S, Miyoshi T, Takubo T, Tsuji M, Hanafusa T. Minimal-change nephrotic syndrome preceding Hodgkin lymphoma by 5 years with expression of tumor necrosis factor α in Hodgkin-Reed-Sternberg cells. Hum Pathol 41: 1196–1199, 2010.
51. Navarro-González JF, Jarque A, Muros M, Mora C, García J. Tumor necrosis factor-α as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev 20: 165–173, 2009.
52. Nijenhuis T, Sloan AJ, Hoenderop JG, Flesche J, van Goor H, Kistler AD, Bakker M, Bindels RJ, de Boer RA, Möller CC, Hamming I, Navis G, Wetzels JF, Berden JH, Reiser J, Faul C, van der Vlag J. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol 179: 1719–1732, 2011.
53. Pestell RG. New roles of cyclin D 1. Am J Pathol 183: 3–9, 2013.
54. Pogan A, Sancewicz-Pach K, Miezyński W. TNF-α and soluble interleukin-2 receptor and glomerular sclerosis in primary nephrotic syndrome in children. Wiad Lek 58, Suppl 1: 39–44, 2005.
55. Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 285: F610–F618, 2003.
56. Ramseyer VD, Garvin JL. Tumor necrosis factor-α: regulation of renal function and blood pressure. Am J Physiol Renal Physiol 304: F1231–F1242, 2013.
57. Reiser J, Polu KR, Möller CC, Kenlan P, Altintas MM, Wei C, Faul C, Herbert S, Villegas I, Avila-Casado C, McGee M, Sugimoto H, Brown D, Kalluri R, Mundel P, Smith PL, Clapham DE, Pollak MR. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 37: 739–744, 2005.
58. Rosa AC, Rattazzi L, Miglio G, Collino M, Fantozzi R. Angiotensin II induces tumor necrosis factor-α expression and release from cultured human podocytes. Inflamm Res 61: 311–317, 2012.
59. Roshanravan H, Dryer SE. ATP acting through P2Y receptors causes activation of podocyte TRPC6 channels: role of podocin and reactive oxygen species. Am J Physiol Renal Physiol 306: F1088–F1097, 2014.
60. Ryu M, Mulay SR, Miosge N, Gross O, Anders HJ. Tumour necrosis factor-α drives Alport glomerulosclerosis in mice by promoting podocyte apoptosis. J Pathol 226: 120–131, 2012.
61. Schlöndorff J, Del Camino D, Carrasquillo R, Lacey V, Pollak MR. TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription. Am J Physiol Cell Physiol 296: C558–C569, 2009.
62. Schust J, Sperl B, Hollis A, Mayer TU, Berg T. Stattic: a smallmolecule inhibitor of STAT3 activation and dimerization. Chem Biol 13: 1235–1242, 2006.
63. Shin HM, Kim MH, Kim BH, Jung SH, Kim YS, Park HJ, Hong JT, Min KR, Kim Y. Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-κB without affecting IκB degradation. FEBS Lett 57: 50–54, 2004.
64. Spriggs DR, Sherman ML, Imamura K, Mohri M, Rodriguez C, Robbins G, Kufe DW. Phospholipase A2 activation and autoinduction of tumor necrosis factor gene expression by tumor necrosis factor. Cancer Res 50: 7101–7177, 1990.
65. Suranyi MG, Guasch A, Hall BM, Myers BD. Elevated levels of tumor necrosis factor-α in the nephrotic syndrome in humans. Am J Kidney Dis 21: 251–259, 1993.
66. Tchakarska G, Roussel M, Troussard X, Sola B. Cyclin D1 inhibits mitochondrial activity in B cells. Cancer Res 71: 1690–1699, 2011.
67. Tian D, Jacobo SM, Billing D, Rozkalne A, Gage SD, Anagnostou T, Pavenstädt H, Hsu HH, Schlondorff J, Ramos A, Greka A. Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels. Sci Signal 3: ra77, 2010.
68. Trask OJ. Nuclear factor kappa B (NF-κB) translocation assay development and validation for high content screening. In: Assay Guidance Manual, edited by Sittampalam GS, Coussens NP, Nelson H. Bethesda, MD: Eli Lilly & Company and the National Center for Advancing Translational Sciences, 2004–2012. http://www.ncbi.nlm.nih.gov/books/NBK100914/.
69. 2+ ATPase expression and leads to left ventricular diastolicdysfunction through binding of NF-κB to promoter response element. Cardiovasc Res 105: 318–329, 2015.
70. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10: 411–452, 1992.
71. Wang Y, Jarad G, Tripathi P, Pan M, Cunningham J, Martin DR, Liapis H, Miner JH, Chen F. Activation of NFAT signaling in podocytes causes glomerulosclerosis. J Am Soc Nephrol 21: 1657–1666, 2010.
72. Wiggins RC. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 71: 1205–1214, 2007.
73. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette JL, Pericak-Vance MA, Howell DN, Vance JM, Rosenberg PB. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308: 1801–1804, 2005.
74. Yu Z, Zhang W, Kone BC. Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor κB. Biochem J 367: 97–105, 2002.
75. Zager RA, Johnson AC, Lund S, Hanson S. Acute renal failure: determinants and characteristics of the injury-induced hyperinflammatory response. Am J Physiol Renal Physiol 291: F546–F556, 2006.
76. Zheng L, Sinniah R, Hsu SI. In situ glomerular expression of activated NF-κB in human lupus nephritis and other non-proliferative proteinuric glomerulopathy. Virchows Arch 448: 172–183, 2006.